Aydilek, Enver; Wulf, Gerald; Schwarz, Friedrich; Bacher, Ulrike; Rummel, Mathias; Stiefel, Olga; Kerkhoff, Andrea; Maulhardt, Markus; Melchardt, Thomas; Pabst, Thomas; Lenz, Georg; Shumilov, Evgenii (2024). Outcomes of pirtobrutinib for relapsed/refractory mantle cell lymphoma in compassionate use program in Europe. Cancer medicine, 13(10) Wiley 10.1002/cam4.7289
|
Text
Cancer_Medicine_-_2024_-_Aydilek_-_Outcomes_of_pirtobrutinib_for_relapsed_refractory_mantle_cell_lymphoma_in_compassionate.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (251kB) | Preview |
BACKGROUND
Mantle cell lymphoma (MCL) is a type of B-cell lymphoma that is currently incurable. Pirtobrutinib shows promising response rates in heavily pretreated MCL patients according to the approval study, but the real-world data are scarce.
METHODS
In this study, we retrospectively analyzed the efficacy and safety profile of pirtobrutinib in 10 relapsed/refractory MCL patients from compassionate use program (CUP).
RESULTS
On average, the patients underwent three lines of systemic therapy prior to pirtobrutinib and were predominantly BTKi exposed (9/10). The best overall response rate (BORR) was 67%. In a median follow-up of 8.6 months, the mean duration of response (DOR), progression-free survival (PFS), and overall survival (OS) were not reached. No new safety signals were documented.
CONCLUSIONS
In summary, pirtobrutinib represented a safe and effective treatment option in a small real-world population.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology 04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Haematology and Central Haematological Laboratory |
UniBE Contributor: |
Bacher, Vera Ulrike, Pabst, Thomas Niklaus |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
2045-7634 |
Publisher: |
Wiley |
Language: |
English |
Submitter: |
Pubmed Import |
Date Deposited: |
22 May 2024 14:59 |
Last Modified: |
23 May 2024 15:25 |
Publisher DOI: |
10.1002/cam4.7289 |
PubMed ID: |
38770551 |
Uncontrolled Keywords: |
compassionate use program mantle cell lymphoma outcomes pirtobrutinib |
BORIS DOI: |
10.48350/196944 |
URI: |
https://boris.unibe.ch/id/eprint/196944 |
Actions (login required)
 |
Edit item |